Shares of Tiziana Life Sciences PLC (LON:TILS) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 95.59 ($1.32) and last traded at GBX 99.85 ($1.38), with a volume of 7175 shares changing hands. The stock had previously closed at GBX 100 ($1.38).
Separately, Beaufort Securities reissued a “speculative buy” rating and issued a GBX 400 ($5.53) price objective on shares of Tiziana Life Sciences in a research report on Tuesday, December 19th.
The firm has a market capitalization of $121.93 and a PE ratio of -1,109.56.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.